While some research indicates a potential link between ARID1A deletion and tumour advancement, other studies suggest that the expression of ARID1A shows a significant rise from normal tissue to non‐invasive urothelial carcinoma and subsequently to invasive urothelial carcinoma; additionally, reduced ARID1A expression appears to indicate a potential association with unfavourable outcomes for individuals diagnosed with bladder cancer [95]. This evidence concerns the gene ARID1A and urinary bladder carcinoma.